Karyotype

Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence

Retrieved on: 
星期三, 四月 17, 2024
Cytogenetics, Pregnancy, NMPA, OGM, Partnership, OEM, Doctor of Philosophy, Research, Artificial intelligence, Karyotype, Fertilisation, Genomics, Bone marrow, SVS, SAN, Medical device

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.

Key Points: 
  • Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.
  • Diagens has received Class I registration and approval for Bionano’s OGM reagents from China's NMPA and will register the Saphyr™ instrument with NMPA for clinical use in reproductive health.
  • “As a pioneer in AI chromosome karyotype analysis, we are very happy to establish a partnership with Bionano and to jointly explore the reproductive health market.
  • Diagens offers cutting-edge AI technology to help our customers to achieve a better overall success rate of in vitro fertilization.

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

Retrieved on: 
星期三, 四月 3, 2024
Sarcoma, Diagnosis, KT, Oncogene, SAN, Neoplasm, Research, Cancer, Doctor of Philosophy, CDKN2A, Workflow, Karyotype, FISH, Genomics, Chromothripsis, SVS, Prognosis, Aberration, OGM, Medical imaging

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.

Key Points: 
  • Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
  • The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques.
  • In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT.
  • As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and ​comprehensive, genome-wide analysis.

Global and Regional MRD Testing Market Analysis Report 2024: Revolutionizing Cancer Patient Management, Rising Consumer Awareness Spurs Demand for MRD Testing - Forecast to 2033 - ResearchAndMarkets.com

Retrieved on: 
星期一, 四月 1, 2024
Surgery, Medical Devices, Hospitals, Genetics, Health Technology, Biotechnology, Radiology, Health, Oncology, Hospital, PCR, Flow cytometry, Chronic leukemia, Growth, Bone marrow, Incidence, Integration, Patient, NGS, IDT, Research, Health care, Multiple myeloma, Acquisition, Cancer, Medicare, Medicine, Karyotype, MRD, Haematopoietic system, Region, GRAIL, Throttle position sensor, Lymphoma, Polymerase chain reaction, Medical imaging

The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The MRD testing market is driven by several factors, including the expansion in medicare coverage for MRD testing and the administration of solid tumor diagnosis.
  • In recent years, as consumer awareness has grown, there has been an increasing demand for MRD testing.
  • The global MRD testing market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients.

Acclaimed Clinical Geneticist Dr. Bruce Korf Honored with 2024 David L. Rimoin Lifetime Achievement Award in Medical Genetics from the ACMG Foundation for Genetic and Genomic Medicine

Retrieved on: 
星期三, 三月 13, 2024
Department of Defence, Friends, Patient, Medical genetics, Travel, Child, Neurofibromatosis, Practice, UAB, Gene expression, Dean (education), Education, Rockefeller University, Seed, NF, NIH, American College, Pediatrics, Person, Karyotype, MD–PhD, Boston Children's Hospital, Principle, Birmingham School of Law, Neurology, FACOG, Genetics, Cornell University, American Journal, Research, Hospital, University, Human genetics, Student, Publication, DRS, ACMG, Book, Genetic distance, DSM-IV codes, Diagnosis, FACMG, Empathy, Montefiore Medical Center, Distinguishing, Mouse, Hope, Doctor of Philosophy, Life, Genetic, Bangladesh Technical Education Board, Physician, Nursing

BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Renowned clinical geneticist Bruce Korf, MD, PhD, FACMG, has been named the recipient of the 2024 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.

Key Points: 
  • BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Renowned clinical geneticist Bruce Korf, MD, PhD, FACMG, has been named the recipient of the 2024 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.
  • Dr. Korf is an authentic, kind and ethical human being whose life and career in medical genetics are unparalleled."
  • "Dr. Korf's extraordinary accomplishments in clinical genetics, neurofibromatosis, and genomics, as well as his dedication to education make him a well deserving winner of the David Rimoin Lifetime Achievement Award.
  • Before he died, David appreciated the opportunity to work with Bruce first-hand in the editing of Principles and Practice of Medical Genetics as well as on numerous committees for the ACMG.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
星期二, 一月 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Retrieved on: 
星期三, 一月 24, 2024
SAN, Standard of care, Fluorescence, University of Rochester, Test management, University, SVS, FISH, Genomics, DSM-IV codes, In situ hybridization, IRB, SOC, Karyotype, CMA, KT, Columbia University, OGM, Clinical trial, Institutional review board, Data, Diagnosis, Medical device

This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.

Key Points: 
  • This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.
  • This second interim readout is designed to evaluate endpoints connected to analytical performance using an expanded dataset in key areas of technical performance and clinical utility of OGM.
  • The study is an Institutional Review Board (IRB)-approved, multicenter, double-blinded trial with samples from 219 unique retrospective (57) and prospective (162) clinical research subjects.
  • All samples had been previously tested with traditional methods including karyotyping (KT), fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA).

Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping

Retrieved on: 
星期二, 十二月 26, 2023
Clutch (eggs), CMA, SVS, OGM, Workflow, Woman, Doctor of Philosophy, SAN, Genomics, PPV, Karyotype, NPV, Orientation, KT

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication covering the largest independent prospective prenatal study comparing optical genome mapping (OGM) to a combined workflow of chromosomal microarray analysis (CMA) and karyotyping (KT). The study highlighted OGM’s high analytical concordance with the combined workflow of CMA and KT, and its ability to detect novel pathogenic structural variants (SVs) missed by those methods. The study also highlighted OGM’s potential to provide additional information about SVs and copy number variants (CNVs) compared to CMA and KT.

Key Points: 
  • The study also highlighted OGM’s potential to provide additional information about SVs and copy number variants (CNVs) compared to CMA and KT.
  • Researchers used 200 unique prospective prenatal samples with soft markers (including increased nuchal translucency, nasal bone hypoplasia and mild ventriculomegaly, and structural anomalies) for the study.
  • “The use of OGM for the analysis of prenatal samples is an area where we believe our workflow can have tremendous global impact.
  • We believe this study marks a milestone in the Chinese prenatal research market as it includes the largest sample size to date for an independent prenatal study using OGM.

Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research

Retrieved on: 
星期四, 十二月 14, 2023
Editorial, Oncology, In situ hybridization, CMA, OGM, SVS, Radboud University Medical Center, Research, Workflow, Fluorescence, DRS, Bone marrow, SAN, Doctor of Philosophy, Chronic lymphocytic leukemia, Multiple myeloma, Genomics, University, Karyotype, CLL, Cytogenetics, FACMG, Growth, University of Toronto, Publication, Acute myeloid leukemia, KT, AML, FISH

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.

Key Points: 
  • SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.
  • “I personally believe the importance of OGM for hematological malignancies research cannot be overstated.
  • The papers published in this dedicated issue elegantly illustrate how information provided by OGM surpasses the capabilities of the current tools in cancer research.
  • “This special edition of Cancers dedicated to OGM is a significant milestone for the technique and for people in the various fields of genome analysis who are looking for ways to move the community forward.

Phase Genomics Advances Breakthrough Cytogenomics with the Element AVITI System for Acute Myeloid Leukemia

Retrieved on: 
星期五, 十一月 17, 2023
Oncology, Health, Genetics, Other Science, Research, Science, Biotechnology, Karyotype, Chromosome, Plant, Acute myeloid leukemia, Collection, Risk, CMA, Cytogenetics, Phase Genomics, Animal, Genomics, Metagenomics, Booth, Genome, Risk assessment, Cancer, AML, Antibiotics, Medical imaging

The platform offers a revolutionary leap toward rapid risk stratification for acute myeloid leukemia (AML).

Key Points: 
  • The platform offers a revolutionary leap toward rapid risk stratification for acute myeloid leukemia (AML).
  • Phase Genomics addresses these legacy challenges with the combination of its OncoTerra technology and Element’s AVITI system for next-generation sequencing, providing a high-resolution alternative for comprehensive, streamlined risk stratification in the research setting.
  • The next-generation cytogenomics all-in-one approach is primed to replace fragmented legacy tests with a single, rapid assay,” said Ivan Liachko, founder and CEO of Phase Genomics.
  • Discover more about next-generation cytogenomics powered by proximity ligation technology in four presentations at AMP23 , or connect with the Phase Genomics team at Booth 810.

Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress

Retrieved on: 
星期三, 十一月 8, 2023
Spectrum, German Cancer Research Center, Aneuploidy, CMA, MCA, OEM, Sale, Genomics, DSM-IV codes, OGM, NMPA, WES, SVS, IVD, Publication, Rare, Polyploidy, CRISPR, Medtech, International Cancer Genome Consortium, Doctor of Philosophy, GAAP, Acquisition, Research, Poster, Karyotype, Lobotomy Corporation, Genome, Nature Communications, National Medical Products Administration, SNV calling from NGS data, Hospital, Annual general meeting, CGC, Workflow, Bone marrow, KT, CFO, Cancer, ASD, Total, VIA, IPSC, Chromosomal deletion syndrome, SAN, DNA, Outline, Beauty salon, Cryptocurrency, Video game, Vaccine, Management, Medical device, Pharmaceutical industry

Publications featuring OGM increased 61% from the third quarter of 2022 to the third quarter of 2023, including a total of 47 human-focused publications.

Key Points: 
  • Publications featuring OGM increased 61% from the third quarter of 2022 to the third quarter of 2023, including a total of 47 human-focused publications.
  • GAAP gross margin for the third quarter of 2023 was 30%, compared to 25% from the third quarter of 2022.
  • Third quarter 2023 non-GAAP¹ gross margin was 32%, compared to 25% from the third quarter of 2022.
  • Third quarter 2023 non-GAAP operating expense was $31.8 million, compared to $26.3 million in the third quarter of 2022 and $34.6 million in the second quarter of 2023.